PE20230388A1 - Inhibidor de ret cristalino - Google Patents

Inhibidor de ret cristalino

Info

Publication number
PE20230388A1
PE20230388A1 PE2022002417A PE2022002417A PE20230388A1 PE 20230388 A1 PE20230388 A1 PE 20230388A1 PE 2022002417 A PE2022002417 A PE 2022002417A PE 2022002417 A PE2022002417 A PE 2022002417A PE 20230388 A1 PE20230388 A1 PE 20230388A1
Authority
PE
Peru
Prior art keywords
crystalline
ret inhibitor
ppm
peaks
selpercatinib
Prior art date
Application number
PE2022002417A
Other languages
English (en)
Inventor
Rajni Miglani Bhardwaj
Mark Steven Kerr
Douglas Patton Kjell
Jeremy Miles Merritt
Jon Gordon Selbo
Shekhar Krishna Viswanath
Original Assignee
Loxo Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Loxo Oncology Inc filed Critical Loxo Oncology Inc
Publication of PE20230388A1 publication Critical patent/PE20230388A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Semiconductor Lasers (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Una forma cristalina de selpercatinib, que se caracteriza por al menos uno de: (a) un patron de difraccion de rayos X en polvo (XRPD) que comprende un pico a 21,1 y uno o mas picos a 17,1 , 17,7 y 19,8 0,2 2? medidos utilizando una longitud de onda de rayos X de 1,5418 ; o (b) un espectro de NMR de 13C en estado solido que comprende picos referidos a la resonancia de campo alto de adamantano (? = 29,5 ppm) a: 28,0, 48,0, 80,4, 106,8, 130,2 y 134,9ppm ( 0,2 ppm, respectivamente).
PE2022002417A 2020-04-17 2021-04-09 Inhibidor de ret cristalino PE20230388A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063011701P 2020-04-17 2020-04-17
US202163151354P 2021-02-19 2021-02-19
PCT/US2021/026611 WO2021211380A1 (en) 2020-04-17 2021-04-09 Crystalline ret inhibitor

Publications (1)

Publication Number Publication Date
PE20230388A1 true PE20230388A1 (es) 2023-03-06

Family

ID=75747118

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022002417A PE20230388A1 (es) 2020-04-17 2021-04-09 Inhibidor de ret cristalino

Country Status (17)

Country Link
EP (1) EP4136090A1 (es)
JP (1) JP2023522012A (es)
KR (1) KR20230002706A (es)
CN (1) CN115916791A (es)
AU (1) AU2021255488B2 (es)
BR (1) BR112022020446A2 (es)
CA (1) CA3174316A1 (es)
CL (1) CL2022002849A1 (es)
CO (1) CO2022014882A2 (es)
CR (1) CR20220520A (es)
DO (1) DOP2022000221A (es)
EC (1) ECSP22080982A (es)
IL (1) IL297212A (es)
MX (1) MX2022012952A (es)
PE (1) PE20230388A1 (es)
TW (1) TW202202501A (es)
WO (1) WO2021211380A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022069357A1 (en) * 2020-10-01 2022-04-07 Sandoz Ag Crystalline form of selpercatinib
US20230183266A1 (en) 2021-12-13 2023-06-15 Loxo Oncology, Inc. Crystalline forms of ret inhibitor and preparation thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TWI783057B (zh) * 2017-10-10 2022-11-11 美商絡速藥業公司 製備6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈的方法
TW202410896A (zh) * 2017-10-10 2024-03-16 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
KR20210070286A (ko) * 2018-09-30 2021-06-14 베이징 즈지엔진루이 셩우이야오 커지 요우시엔공스 치환된 피라졸 융합고리계 유도체 및 이의 제조 방법과 응용
CN111004257B (zh) * 2019-12-24 2021-06-29 武汉九州钰民医药科技有限公司 制备RET抑制剂Selpercatinib的方法

Also Published As

Publication number Publication date
EP4136090A1 (en) 2023-02-22
KR20230002706A (ko) 2023-01-05
WO2021211380A1 (en) 2021-10-21
CA3174316A1 (en) 2021-10-21
JP2023522012A (ja) 2023-05-26
BR112022020446A2 (pt) 2022-11-29
CL2022002849A1 (es) 2023-06-16
CR20220520A (es) 2022-11-15
ECSP22080982A (es) 2023-01-31
CN115916791A (zh) 2023-04-04
AU2021255488A1 (en) 2022-11-10
DOP2022000221A (es) 2023-01-15
MX2022012952A (es) 2023-01-11
CO2022014882A2 (es) 2022-10-31
IL297212A (en) 2022-12-01
AU2021255488B2 (en) 2024-05-30
TW202202501A (zh) 2022-01-16

Similar Documents

Publication Publication Date Title
PE20230388A1 (es) Inhibidor de ret cristalino
CN109313404B (zh) 辐射源
Tong et al. Probing the spectral and temporal structures of high-order harmonic generation in intense laser pulses
CL2021000361A1 (es) Nuevos compuestos heterocíclicos como inhibidores de monoacilglicerol lipasa
Macrander et al. X-ray optics testing beamline 1-BM at the advanced photon source
CR20140215A (es) Ciclopenta (d) pirimidinas como inhibidores de la proteina cinasa akt
CN103149809B (zh) 光刻机设备用离轴照明装置
Brown Synchrotron Emission on the Largest Scales: Radio Detection of the Cosmic-Web
JP6909873B2 (ja) アライメント測定システム
DE60331310D1 (de) Verfahren zum apoptosenachweis
Takano Beam diagnostics with synchrotron radiation in light sources
WO2015019187A3 (en) System and method for return beam metrology with optical switch
WO2014128010A8 (en) Euv light source for generating a used output beam for a projection exposure apparatus
ES2603219T3 (es) Procedimiento y dispositivo de transmisión de ondas
TW200630604A (en) Method and apparatus for inspection of optical component
CN113126205B (zh) 一种基于光开关的分段式平面成像系统及方法
CL2022001087A1 (es) Cristal de 3-(difluorometil)-1-metil-n-(1,1,3-trimetil-2,3-dihidro-1h-inden-4-il)-1h-pirazol-4-carboxamida
Shu-Min et al. Developments at SSRF in soft x-ray interference lithography
KR101357883B1 (ko) 시간 분해능을 이용한 다중 간섭 장치
Lommen et al. Correlation between X-ray light-curve shape and radio arrival time in the Vela pulsar
Xie et al. The Doppler effect and spectral energy distribution of blazars
Liu et al. Intensive Swift and LCO monitoring of PG 1302$-$102: AGN disk reverberation mapping of a supermassive black hole binary candidate
Ahmed et al. An efficient spectral amplitude coding (sac) technique for optical cdma system using wavelength division multiplexing (wdm) concepts
Schott Recent electroweak results from ATLAS at PLHC 2011
NIKOLENKO et al. Synchrotron radiation metrological station Cosmos at the VEPP-4 storage ring: current status and prospects